arBtrage CAPITALIZING MARKETS checking… Sign in

Kyverna Therapeutics, Inc.

KYTX Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$7.47
▼ -6.0% Today
as of Jun 7, 07:19 ET
Last 30 days -14.14% Apr 28 → Jun 05
$7.21 $8.17 $9.12 $10.08 $11.04 Apr 28 May 05 May 13 May 20 May 29 Jun 05
Open
$7.96
High
$7.96
Low
$7.44
Volume
$597,925
Avg Vol
$874,352
Mkt Cap
$526M
P/E (TTM)
Beta
52w High
$13.67
52w Low
$2.52
Div Yield
Shares Out
$61M

Overview

52-week range
$2.52
$14
44% of range
Avg surprise (last 2)
+13.4%
Avg reaction (last 2)
+2.0%
50% positive
Latest IV / EM
77%
EM ±10.7% · $8 · Jun 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-23.27$-17.62$-11.96$-6.31$-0.66 Actual $-20.86Actual $-23.27Actual $-1.12Actual $-0.67Actual $-0.80Actual $-1.03Est $-1.21Actual $-0.97Actual $-0.85Actual $-0.66Est $-0.75 JunSepMarJunSepMar/2025JunSepMar/2026
Revenue vs Net Income Revenue Net income
$-45M$-41M$-37M$-34M$-30M Jun 24Sep 24Mar 25Jun 25Sep 25Mar 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue May 12, 2026Mar/2026 $-0.66 $-0.75 +12.0% +35.9% -1.1% earnings
Tue Sep 30, 2025Sep 2025 $-0.85 financials
Mon Jun 30, 2025Jun 2025 $-0.97 financials
Tue May 13, 2025Mar/2025 $-1.03 $-1.21 +14.9% +5.0% earnings
Mon Sep 30, 2024Sep 2024 $-0.80 financials
Sun Jun 30, 2024Jun 2024 $-0.67 financials
Sun Mar 31, 2024Mar 2024 $-1.12 financials
Sat Sep 30, 2023Sep 2023 $-23.27 financials
Fri Jun 30, 2023Jun 2023 $-20.86 financials

Financials

Income statement (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue
Cost of revenue
Gross profit
Operating income$-41M$-39M$-44M$-47M$-39M$-33M
Net income$-40M$-37M$-42M$-45M$-34M$-29M
EPS (diluted)$-0.66$-0.85$-0.97$-1.03$-0.80$-0.67

Balance sheet (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Cash & equivalents$32M$124M$34M$53M$57M$97M$105M$132M
Inventory
Total current assets$242M$283M$175M$214M$248M$291M$325M$349M
Total assets$257M$294M$187M$227M$261M$305M$339M$363M
Long-term debt
Total liabilities$61M$62M$35M$42M$37M$38M$36M$30M
Total equity$196M$232M$152M$184M$224M$267M$303M$334M

Implied volatility — last 90 days

72%74%77%79%82% Jun 07 — IV 77% · EM ±10.7%

Sector peers